https://www.selleckchem.com/pr....oducts/cdk2-inhibito
8months vs. 11.1months, p0.001) and PFS (10.4months vs. 5.5months, p0.001) were significantly longer in patients with TFA-irAEs than in those without TFA-irAEs. In subgroup analysis of hypothyroidism and hyperthyroidism groups, similar trends were also obtained for both OS and PFS. After adjusting for potential confounding variables, patients with TFA-irAEs had a lower mortality risk (HR 0.334, 95%CI 0.196-0.571) than those without TFA-irAEs. TFA-irAEs is associated with enhanced PD-1 inhibitor efficacy in advanced NSC
Like
Comment
Share
